XNASLVTX
Market cap25mUSD
Dec 23, Last price
0.98USD
1D
-4.49%
1Q
-41.79%
IPO
-92.97%
Name
LAVA Therapeutics NV
Chart & Performance
P/E
—
P/S
3.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
7m
-65.09%
Net income
-42m
L+31.55%
CFO
-39m
L
Earnings
Mar 18, 2025
Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 6,769 -65.09% | 19,391 262.45% | 5,350 42.78% | ||
Cost of revenue | 50,022 | 54,229 | 48,963 | ||
Unusual Expense (Income) | |||||
NOPBT | (43,253) | (34,838) | (43,613) | ||
NOPBT Margin | |||||
Operating Taxes | 279 | 249 | 157 | ||
Tax Rate | |||||
NOPAT | (43,532) | (35,087) | (43,770) | ||
Net income | (41,974) 31.55% | (31,907) -24.67% | (42,355) 165.93% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 106,783 | ||||
BB yield | -98.26% | ||||
| Debt | |||||
Debt current | 5,722 | 5,019 | |||
Long-term debt | 1,622 | 1,241 | |||
Deferred revenue | 35,000 | 35,000 | |||
Other long-term liabilities | 4,732 | 11,401 | |||
Net debt | (88,227) | (126,608) | (151,014) | ||
| Cash flow | |||||
Cash from operating activities | (38,972) | 4,043 | (32,477) | ||
CAPEX | (730) | (587) | |||
Cash from investing activities | (17,635) | 9,346 | (49,367) | ||
Cash from financing activities | (571) | 283 | 171,372 | ||
FCF | (43,943) | (34,259) | (46,681) | ||
| Balance | |||||
Cash | 95,571 | 132,868 | 151,014 | ||
Long term investments | |||||
Excess cash | 95,233 | 131,898 | 150,746 | ||
Stockholders' equity | (155,251) | (108,384) | (89,260) | ||
Invested Capital | 247,742 | 239,561 | 247,126 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 26,733 | 25,924 | 19,758 | ||
Price | 1.58 -54.86% | 3.50 -36.36% | 5.50 | ||
Market cap | 42,237 -53.45% | 90,734 -16.50% | 108,670 | ||
EV | (45,990) | (35,874) | (42,344) | ||
EBITDA | (41,975) | (34,057) | (43,613) | ||
EV/EBITDA | 1.10 | 1.05 | 0.97 | ||
Interest | |||||
Interest/NOPBT | |||||